`16117
`
`
`
`
`
`
`
`EXHIBIT A
`
`
`
`
`
`Case 1:23-cv-00089-TSK-JPM Document 128-1 Filed 03/06/24 Page 2 of 11 PageID #:
`16118
`
`Beazley, Jennalee
`From:
`Lauren M. Lesko <LLesko@rmmslegal.com>
`Sent:
`Tuesday, March 5, 2024 10:19 PM
`To:
`Gregory, Teagan; M710 Team; Gordon Copland; Jamie O'Brien
`Cc:
`Eylea; Steve Ruby; David Pogue
`Subject:
`RE: Regeneron v. Mylan - Redactions
`
`Teagan,
`
`We write concerning the list of materials identified in your February 21 correspondence. While our review of
`those materials is ongoing, we confirm that the below-referenced documents do not contain Defendants’
`confidential information:
`
`
` Regeneron’s Second Set of Interrogatories to Mylan Pharmaceuticals Inc. (Nos. 3-4) (Nov. 23, 2022)
` Regeneron’s Third Set of Interrogatories to Mylan Pharmaceuticals Inc. (No. 5) (Dec. 12, 2022)
` Mylan Pharmaceuticals Inc.’s First Set of Interrogatories to Regeneron Pharmaceuticals, Inc. (Nos. 1-
`17) (Dec. 13, 2022)
` Mylan Pharmaceuticals Inc.’s Answers and Objections to Regeneron’s Second Set of Interrogatories
`(Nos. 3-4) (Dec. 23, 2022)
` Mylan Pharmaceuticals Inc.’s Answers and Objections to Regeneron’s Third Set of Interrogatories (No.
`5) (Jan. 11, 2023)
` Regeneron Pharmaceuticals, Inc.’s Objections and Responses to Defendant’s First Set of Interrogatories
`(Nos. 1-17) (Jan. 12, 2023)
` Regeneron Pharmaceuticals, Inc.’s Objections and Responses to Defendant’s Second Set of
`Interrogatories (Nos. 18-24) (Jan. 18, 2023)
` Mylan Pharmaceuticals Inc.’s First Set of Requests for Admission to Regeneron Pharmaceuticals, Inc.
`(Nos. 1-35) (Dec. 13, 2022)
` Regeneron Pharmaceuticals, Inc.’s Responses and Objections to Mylan Pharmaceuticals Inc.’s First
`Requests for Admission (Nos. 1-35) (Jan. 12, 2023)
` Transcript and exhibits from the deposition of Hanne Bak
` Transcript and exhibits from the deposition of Abby Cahn
` Transcript and exhibits from the deposition of Eric Furfine
` Transcript and exhibits from the deposition of Kenneth Graham
` Transcript and exhibits from the deposition of Amy Johnson
` Transcript and exhibits from the deposition of Shawn Lawrence
` Transcript and exhibits from the deposition of George Yancopoulos
`
`
`We are available to discuss if you have any questions.
`
`Best,
`Lauren
`
`
`L A U R E N M . L E S K O | P A R T N E R
`L L E S K O @ R M M S L E G A L . C O M
`D I R E C T | 3 1 2 . 2 2 2 . 7 2 4 5
`M O B I L E | 6 3 0 . 2 0 5 . 2 3 9 0
`
`1
`
`
`
`Case 1:23-cv-00089-TSK-JPM Document 128-1 Filed 03/06/24 Page 3 of 11 PageID #:
`16119
`
`S I X W E S T H U B B A R D S T R E E T | C H I C A G O I L 6 0 6 5 4
`W W W . R M M S L E G A L . C O M
`
`
`
`
`
`This email message and any attachments are being sent by Rakoczy Molino Mazzochi
`Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient,
`please notify us immediately by replying to this message, and destroy all copies of this
`message and any attachments. Thank you.
`From: Gregory, Teagan <TGregory@wc.com>
`Sent: Tuesday, February 27, 2024 2:59 PM
`To: Lauren M. Lesko <LLesko@rmmslegal.com>; M710 Team <M710Team@rmmslegal.com>; Gordon Copland
`<Gordon.Copland@Steptoe‐Johnson.com>; Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>
`Cc: Eylea <Eylea@wc.com>; Steve Ruby <sruby@cdkrlaw.com>; David Pogue <drpogue@cdkrlaw.com>
`Subject: RE: Regeneron v. Mylan ‐ Redactions
`
`Lauren,
`
`Do Defendants have any update on the timing of the review you indicate is underway?
`
`Thanks,
`Teagan
`
`Teagan James Gregory
`Williams & Connolly LLP
`680 Maine Avenue SW, Washington, DC 20024
`(P) 202‐434‐5178 | (F) 202‐434‐5029
`tgregory@wc.com | www.wc.com/tgregory
`
`From: Gregory, Teagan <TGregory@wc.com>
`Sent: Friday, February 23, 2024 8:26 AM
`To: Lauren M. Lesko <LLesko@rmmslegal.com>; M710 Team <M710Team@rmmslegal.com>; Gordon Copland
`<Gordon.Copland@Steptoe‐Johnson.com>; Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>
`Cc: Eylea <Eylea@wc.com>; Steve Ruby <sruby@cdkrlaw.com>; David Pogue <drpogue@cdkrlaw.com>
`Subject: RE: Regeneron v. Mylan ‐ Redactions
`
`Lauren,
`
`Your email was received, and we will await your further correspondence.
`
`Teagan
`
`
`
`From: Lauren M. Lesko <LLesko@rmmslegal.com>
`Date: Thursday, Feb 22, 2024 at 1:46 PM
`
`2
`
`
`
`Case 1:23-cv-00089-TSK-JPM Document 128-1 Filed 03/06/24 Page 4 of 11 PageID #:
`16120
`To: Gregory, Teagan <TGregory@wc.com>, M710 Team <M710Team@rmmslegal.com>, Gordon Copland
`<Gordon.Copland@Steptoe‐Johnson.com>, Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>
`Cc: Eylea <Eylea@wc.com>, Steve Ruby <sruby@cdkrlaw.com>, David Pogue <drpogue@cdkrlaw.com>
`Subject: RE: Regeneron v. Mylan ‐ Redactions
`
`Teagan:
`
`
` more detailed response is forthcoming – in the meantime, Biocon and Mylan do not consent to Regeneron
`producing any of the documents identified in your list below. We are endeavoring to review your requests
`promptly, including your newly-added requests from last night. However, Regeneron is seeking to produce
`documents that implicate Biocon/Mylan Confidential Information to direct competitors, and we therefore
`require a reasonable amount of time to carefully review your voluminous requests in order to ensure that our
`information is properly maintained as confidential.
`
`
`Please immediately confirm that Regeneron has received this email and that Regeneron will not produce any of
`the below documents in “other biosimilar litigations” until we expressly authorize such production.
`
`
`Best,
`Lauren
`
`
`L A U R E N M . L E S K O | P A R T N E R
`L L E S K O @ R M M S L E G A L . C O M
`D I R E C T | 3 1 2 . 2 2 2 . 7 2 4 5
`M O B I L E | 6 3 0 . 2 0 5 . 2 3 9 0
`
` A
`
`S I X W E S T H U B B A R D S T R E E T | C H I C A G O I L 6 0 6 5 4
`W W W . R M M S L E G A L . C O M
`
`
`
`This email message and any attachments are being sent by Rakoczy Molino Mazzochi
`Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient,
`please notify us immediately by replying to this message, and destroy all copies of this
`message and any attachments. Thank you.
`From: Gregory, Teagan <TGregory@wc.com>
`Sent: Wednesday, February 21, 2024 9:35 PM
`To: Lauren M. Lesko <LLesko@rmmslegal.com>; M710 Team <M710Team@rmmslegal.com>; Gordon Copland
`<Gordon.Copland@Steptoe‐Johnson.com>; Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>
`Cc: Eylea <Eylea@wc.com>; Steve Ruby <sruby@cdkrlaw.com>; David Pogue <drpogue@cdkrlaw.com>
`Subject: RE: Regeneron v. Mylan ‐ Redactions
`
`
`Counsel:
`
`
`Thank you for providing a redacted copy of Dr. Swartzwelder’s responsive report. I am writing now to follow up on the
`additional documents that I identified on January 27 and inquire about the next steps for filing redacted versions of
`certain docket entries pursuant to the Court’s Orders regarding the motions to intervene.
`
`
`3
`
`
`
`Case 1:23-cv-00089-TSK-JPM Document 128-1 Filed 03/06/24 Page 5 of 11 PageID #:
`16121
`First, regarding the latter point, our last correspondence regarding unsealing/redacting certain docket entries was on
`January 24 when we confirmed that the Joint Motion regarding unsealing could be filed. Now that the Court has
`granted this Joint Motion and the identified docket entries have been unsealed, how does Mylan propose to proceed
`with reviewing and filing redacted versions of the remaining docket entries pursuant to the Court’s Orders?
`
`
`Next, on January 27 Regeneron identified the following documents it believes may contain information Defendants view
`as confidential. To expedite your review of these documents, as you requested, I have removed from the list the
`documents that we have found on the public docket or, in the case of Dr. Swartzwelder’s responsive report, that you
`have already provided. Please either provide redacted versions or confirm that there is no Defendant confidential
`information in the remaining documents. Please note that pursuant to specific requests we have received, we added
`Mylan Pharmaceutical Inc.’s invalidity contentions to this list.
`
`
` Interrogatories and responses
`o Regeneron’s Fourth Set of Interrogatories to Mylan Pharmaceuticals Inc. (Nos. 6‐14) (Dec. 19,
`2022)
`o Mylan Pharmaceuticals Inc.’s Answers and Objections to Regeneron’s Fourth Set of
`Interrogatories (Nos. 6‐14) (Jan. 18, 2023)
` Requests for admission and responses
`o Regeneron’s First Requests for Admission to Mylan Pharmaceuticals Inc. (Nos. 1‐21) (Nov. 14,
`2022)
`o Mylan Pharmaceuticals Inc.’s Responses and Objections to Plaintiff’s First Requests for Admission
`(Nos. 1‐21) (Dec. 16, 2022)
`o Regeneron’s Second Requests for Admission to Mylan Pharmaceuticals Inc. (Nos. 22‐39) (Dec. 7,
`2022)
`o Mylan Pharmaceuticals Inc.’s Responses and Objections to Regeneron’s Second Requests for
`Admission (Nos. 22‐39) (Jan. 6, 2023)
` Those portions of Defendants’ Invalidity Contentions addressing US Patent Nos.:
` 11,084,865
` 11,104,715
` Patent dance contentions
`o Those portions of Defendants’ detailed statements pursuant to 42 U.S.C. § 262(l)(3)(B) addressing
`US Patent Nos.:
` 11,084,865
` 11,104,715
`o Those portions of Regeneron’s detailed statement pursuant to 42 U.S.C. § 262(l)(3)(C) addressing
`US Patent Nos.:
` 11,084,865
` 11,104,715
` Trial demonstratives
`o DDX‐1 (Opening)
`o DDX‐8 (MacMichael)
`o DDX‐10 (MacMichael)
`o DDX‐14 (Closing Infringement)
`o PDX‐1 (Opening)
`o PDX‐5 (Trout)
`o PDX‐10 (Closing Infringement)
`o PDX‐11 (Closing Validity)
` Deposition materials – transcripts and exhibits from the depositions of:
`o Richard Manning
`o Frank Swartzwelder
`o Bernhardt Trout
` Expert reports
`
`4
`
`
`
`Case 1:23-cv-00089-TSK-JPM Document 128-1 Filed 03/06/24 Page 6 of 11 PageID #:
`16122
`o Trout Opening Report
`o Trout Reply Report
`o Swartzwelder Opening Report
`o Swartzwelder Reply Report
`o Godia Opening Report
`o Godia Supplemental Report
`o Ryder Responsive Report
`o MacMichael Responsive Report
`o MacMichael Supplemental Responsive Report
`
`Finally, below is the list of the documents that Regeneron has identified as potentially responsive and that it believes do
`not contain information Defendants view as confidential. I have also removed the documents that we have found on
`the public docket from this list. Unless Defendants object, we may produce these documents in other biosimilar
`litigations as early as Friday, February 23. If you do object to Regeneron producing any of these documents please
`indicate which documents contain information Defendants view as confidential and provide redacted versions of these
`documents. Please note that we have removed Regeneron’s Closing Validity Slides (PDX‐11) from this list and added it to
`the list above.
`
`
` Interrogatories and responses
`o Regeneron’s Second Set of Interrogatories to Mylan Pharmaceuticals Inc. (Nos. 3‐4) (Nov. 23,
`2022): Mylan indicated this could be unsealed in the 1/25/24 Joint Motion Regarding Unsealing
`Certain Docket Entries. The Court, however, appears to have not yet unsealed this document on
`the public docket. (Dkt. 335‐3)
`o Regeneron’s Third Set of Interrogatories to Mylan Pharmaceuticals Inc. (No. 5) (Dec. 12, 2022):
`Mylan indicated this could be unsealed in the 1/25/24 Joint Motion Regarding Unsealing Certain
`Docket Entries. The Court, however, appears to have not yet unsealed this document on the
`public docket. (Dkt. 335‐4)
`o Mylan Pharmaceuticals Inc.’s First Set of Interrogatories to Regeneron Pharmaceuticals, Inc. (Nos.
`1‐17) (Dec. 13, 2022)
`o Mylan Pharmaceuticals Inc.’s Answers and Objections to Regeneron’s Second Set of
`Interrogatories (Nos. 3‐4) (Dec. 23, 2022)
`o Mylan Pharmaceuticals Inc.’s Answers and Objections to Regeneron’s Third Set of Interrogatories
`(No. 5) (Jan. 11, 2023)
`o Regeneron Pharmaceuticals, Inc.’s Objections and Responses to Defendant’s First Set of
`Interrogatories (Nos. 1‐17) (Jan. 12, 2023)
`o Regeneron Pharmaceuticals, Inc.’s Objections and Responses to Defendant’s Second Set of
`Interrogatories (Nos. 18‐24) (Jan. 18, 2023)
` Requests for admission and responses
`o Mylan Pharmaceuticals Inc.’s First Set of Requests for Admission to Regeneron Pharmaceuticals,
`Inc. (Nos. 1‐35) (Dec. 13, 2022)
`o Regeneron Pharmaceuticals, Inc.’s Responses and Objections to Mylan Pharmaceuticals Inc.’s First
`Requests for Admission (Nos. 1‐35) (Jan. 12, 2023)
` Trial demonstratives
`o DDX‐4 (Rabinow)
`o DDX‐14 (Closing Validity)
`o PDX‐9 Trout
` Deposition materials – transcripts and exhibits from the depositions of:
`o Hanne Bak
`o Abby Cahn
`o Jennifer Colyer
`o Eric Furfine
`
`5
`
`
`
`Case 1:23-cv-00089-TSK-JPM Document 128-1 Filed 03/06/24 Page 7 of 11 PageID #:
`16123
`o Kenneth Graham
`o Amy Johnson
`o Shawn Lawrence
`o George Yancopoulos
` Expert reports
`o Trout Responsive Report
`o MacMichael Opening Report (assuming Mylan’s constructions)
`o MacMichael Opening Report (assuming Regeneron’s constructions)
`o Rabinow Opening Report (assuming Mylan’s constructions)
`o Rabinow Opening Report (assuming Regeneron’s constructions)
`o Godia Reply Report
`
`
`
`Please let us know if you would like to discuss any of the above.
`
`
`Regards,
`Teagan
`
`
`
`Teagan James Gregory
`Williams & Connolly LLP
`680 Maine Avenue SW, Washington, DC 20024
`(P) 202‐434‐5178 | (F) 202‐434‐5029
`tgregory@wc.com | www.wc.com/tgregory
`
`
`From: Lauren M. Lesko <LLesko@rmmslegal.com>
`Sent: Sunday, February 11, 2024 9:04 PM
`To: Gregory, Teagan <TGregory@wc.com>; M710 Team <M710Team@rmmslegal.com>; Gordon Copland
`<Gordon.Copland@Steptoe‐Johnson.com>; Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>
`Cc: Eylea <Eylea@wc.com>; Steve Ruby <sruby@cdkrlaw.com>; David Pogue <drpogue@cdkrlaw.com>
`Subject: RE: Regeneron v. Mylan ‐ Redactions
`
`
`Teagan,
`
`
`As requested in your February 7 email, Defendants are providing a copy of Dr. Swartzwelder’s responsive
`report with Defendants’ confidential information redacted.
`
`
`As for the remainder of the requests, we are reviewing the materials requested and will follow up after we
`complete our review process. As a preliminary matter, we are surprised by Regeneron’s suggestion that
`Defendants may not view Regeneron’s Closing Validity Slides (PDX-11) as confidential. To reiterate what has
`already been the subject of extensive discussion between the parties: PDX-11 contains Defendants’ confidential
`information. Second, we note that many of the requested documents are already on the public docket in
`redacted form. To the extent Regeneron wishes to provide a narrowed list of documents after consulting the
`public docket, that may expedite Defendants’ review.
`
`
`Best,
`Lauren
`
`
`L A U R E N M . L E S K O | P A R T N E R
`L L E S K O @ R M M S L E G A L . C O M
`D I R E C T | 3 1 2 . 2 2 2 . 7 2 4 5
`
`6
`
`
`
`Case 1:23-cv-00089-TSK-JPM Document 128-1 Filed 03/06/24 Page 8 of 11 PageID #:
`16124
`
`M O B I L E | 6 3 0 . 2 0 5 . 2 3 9 0
`
`S I X W E S T H U B B A R D S T R E E T | C H I C A G O I L 6 0 6 5 4
`W W W . R M M S L E G A L . C O M
`
`
`
`This email message and any attachments are being sent by Rakoczy Molino Mazzochi
`Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient,
`please notify us immediately by replying to this message, and destroy all copies of this
`message and any attachments. Thank you.
`From: Gregory, Teagan <TGregory@wc.com>
`Sent: Wednesday, February 7, 2024 3:53 PM
`To: M710 Team <M710Team@rmmslegal.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; Jamie
`O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>
`Cc: Eylea <Eylea@wc.com>; Steve Ruby <sruby@cdkrlaw.com>; David Pogue <drpogue@cdkrlaw.com>
`Subject: RE: Regeneron v. Mylan ‐ Redactions
`
`
`Counsel,
`
`I write to follow‐up on my email of January 27. Among other things, we must produce a copy of the Swartzwelder
`Responsive Report in other biosimilar litigations. Please provided a redacted copy by Monday, February 12.
`
`
`Regards,
`Teagan
`
`
`Teagan James Gregory
`Williams & Connolly LLP
`680 Maine Avenue SW, Washington, DC 20024
`(P) 202‐434‐5178 | (F) 202‐434‐5029
`tgregory@wc.com | www.wc.com/tgregory
`
`
`From: Gregory, Teagan
`Sent: Saturday, January 27, 2024 2:11 PM
`To: M710 Team <M710Team@rmmslegal.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; Jamie
`O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>
`Cc: Eylea <Eylea@wc.com>; Steve Ruby <sruby@cdkrlaw.com>; David Pogue <drpogue@cdkrlaw.com>
`Subject: Regeneron v. Mylan ‐ Redactions
`
`
`Counsel,
`
`Regeneron has received requests for production in Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis, Co., Ltd., Civil
`Action No. 1:23‐cv‐00094‐TSK (N.D. W. Va.), Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis Co., Ltd., Civil Action
`No. 1:23‐cv‐00106‐TSK (N.D. W. Va.), Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc., Civil Action No. 1:23‐cv‐00089‐
`TSK (N.D. W. Va.), and Regeneron Pharmaceuticals, Inc. v. Formycon AG, Civil Action No. 1:23‐cv‐00097‐TSK (N.D. W. Va.)
`seeking the production of various documents filed, served, or used at trial by the parties in the present
`matter. Regeneron wishes to produce documents responsive to these requests but believes a number of the requested
`documents may contain Defendants’ confidential information.
`
`7
`
`
`
`Case 1:23-cv-00089-TSK-JPM Document 128-1 Filed 03/06/24 Page 9 of 11 PageID #:
`16125
`
`
`
`Regeneron therefore has identified the following potentially responsive documents it believes may contain information
`Defendants view as confidential. Please either provide redacted versions of these documents or confirm that there is no
`Defendant confidential information in these materials:
`
`
`
`
`Interrogatories and responses
`o Regeneron’s Fourth Set of Interrogatories to Mylan Pharmaceuticals Inc. (Nos. 6‐14) (Dec. 19, 2022)
`o Mylan Pharmaceuticals Inc.’s Answers and Objections to Regeneron’s Fourth Set of Interrogatories (Nos.
`6‐14) (Jan. 18, 2023)
` Requests for admission and responses
`o Regeneron’s First Requests for Admission to Mylan Pharmaceuticals Inc. (Nos. 1‐21) (Nov. 14, 2022)
`o Mylan Pharmaceuticals Inc.’s Responses and Objections to Plaintiff’s First Requests for Admission (Nos.
`1‐21) (Dec. 16, 2022)
`o Regeneron’s Second Requests for Admission to Mylan Pharmaceuticals Inc. (Nos. 22‐39) (Dec. 7, 2022)
`o Mylan Pharmaceuticals Inc.’s Responses and Objections to Regeneron’s Second Requests for Admission
`(Nos. 22‐39) (Jan. 6, 2023)
` Patent dance contentions
`o Those portions of Defendants’ detailed statements pursuant to 42 U.S.C. § 262(l)(3)(B) addressing US
`Patent Nos.:
` 11,053,280
` 11,084,865
` 11,104,715
` 11,299,532
` 11,459,374
` 11,472,861
`o Those portions of Regeneron’s detailed statement pursuant to 42 U.S.C. § 262(l)(3)(C) addressing US
`Patent Nos.:
` 11,053,280
` 11,084,865
` 11,104,715
` Trial demonstratives
`o DDX‐1 (Opening)
`o DDX‐8 (MacMichael)
`o DDX‐10 (MacMichael)
`o DDX‐14 (Closing Infringement)
`o PDX‐1 (Opening)
`o PDX‐5 (Trout)
`o PDX‐10 (Closing Infringement)
` Deposition materials – transcripts and exhibits from the depositions of:
`o Richard Manning
`o Frank Swartzwelder
`o Bernhardt Trout
` Expert reports
`o Trout Opening Report
`o Trout Reply Report
`o Swartzwelder Opening Report
`o Swartzwelder Responsive Report
`o Swartzwelder Reply Report
`o Godia Opening Report
`o Godia Supplemental Report
`o Ryder Responsive Report
`o MacMichael Responsive Report
`
`8
`
`
`
`Case 1:23-cv-00089-TSK-JPM Document 128-1 Filed 03/06/24 Page 10 of 11 PageID #:
`16126
`o MacMichael Supplemental Responsive Report
`
`
`
`Regeneron also has identified the following potentially responsive documents it believes do not contain information
`Defendants view as confidential. Please either confirm they do not contain Defendants’ confidential information or
`provide redacted versions:
`
`
`
`
`Interrogatories and responses
`o Regeneron’s First Set of Interrogatories to Mylan Pharmaceuticals Inc. (Nos. 1‐2) (Aug. 31, 2022)
`o Mylan Pharmaceuticals Inc. Answers and Objections to Regeneron’s First Set of Interrogatories (Nos. 1‐
`2) (Sept. 30, 2022)
`o Regeneron’s Second Set of Interrogatories to Mylan Pharmaceuticals Inc. (Nos. 3‐4) (Nov. 23, 2022)
`o Regeneron’s Third Set of Interrogatories to Mylan Pharmaceuticals Inc. (No. 5) (Dec. 12, 2022)
`o Mylan Pharmaceuticals Inc.’s First Set of Interrogatories to Regeneron Pharmaceuticals, Inc. (Nos. 1‐17)
`(Dec. 13, 2022)
`o Mylan Pharmaceuticals Inc.’s Second Set of Interrogatories to Regeneron Pharmaceuticals, Inc. (Nos. 18‐
`24) (Dec. 19, 2022)
`o Mylan Pharmaceuticals Inc.’s Answers and Objections to Regeneron’s Second Set of Interrogatories
`(Nos. 3‐4) (Dec. 23, 2022)
`o Mylan Pharmaceuticals Inc.’s Answers and Objections to Regeneron’s Third Set of Interrogatories (No. 5)
`(Jan. 11, 2023)
`o Regeneron Pharmaceuticals, Inc.’s Objections and Responses to Defendant’s First Set of Interrogatories
`(Nos. 1‐17) (Jan. 12, 2023)
`o Regeneron Pharmaceuticals, Inc.’s Objections and Responses to Defendant’s Second Set of
`Interrogatories (Nos. 18‐24) (Jan. 18, 2023)
` Requests for admission and responses
`o Mylan Pharmaceuticals Inc.’s First Set of Requests for Admission to Regeneron Pharmaceuticals, Inc.
`(Nos. 1‐35) (Dec. 13, 2022)
`o Regeneron Pharmaceuticals, Inc.’s Responses and Objections to Mylan Pharmaceuticals Inc.’s First
`Requests for Admission (Nos. 1‐35) (Jan. 12, 2023)
` Trial demonstratives
`o DDX‐4 (Rabinow)
`o DDX‐14 (Closing Validity)
`o PDX‐9 Trout
`o PDX‐11 (Closing Validity)
` Deposition materials – transcripts and exhibits from the depositions of:
`o Hanne Bak
`o Abby Cahn
`o
`Jennifer Colyer
`o Eric Furfine
`o Kenneth Graham
`o Amy Johnson
`o Shawn Lawrence
`o George Yancopoulos
` Expert reports
`o Trout Responsive Report
`o MacMichael Opening Report (assuming Mylan’s constructions)
`o MacMichael Opening Report (assuming Regeneron’s constructions)
`o Rabinow Opening Report (assuming Mylan’s constructions)
`o Rabinow Opening Report (assuming Regeneron’s constructions)
`o Godia Reply Report
`
`
`
`Thanks,
`
`9
`
`
`
`Case 1:23-cv-00089-TSK-JPM Document 128-1 Filed 03/06/24 Page 11 of 11 PageID #:
`16127
`
`Teagan
`
`
`Teagan James Gregory
`Williams & Connolly LLP
`680 Maine Avenue SW, Washington, DC 20024
`(P) 202‐434‐5178 | (F) 202‐434‐5029
`tgregory@wc.com | www.wc.com/tgregory
`
`
`
`
`This message and any attachments are intended only for the addressee and may contain information that is privileged and
`confidential. If you have received this message in error, please do not read, use, copy, distribute, or disclose the contents of the
`message and any attachments. Instead, please delete the message and any attachments and notify the sender immediately. Thank
`you.
`
`10
`
`